ANN ARBOR ? Roger Newton, who sold his drug development company two years ago to Pfizer for $1.3 billion, will deliver the keynote speech at MichBio?s Student Career Day Sept. 28 at Wayne State University. Newton will moderate a panel of drug discovery scientists who will take students through the process of developing a medication
KALAMAZOO ? Some $4 billion in cuts by Pfizer, Michigan?s largest drug development company, could eliminate jobs in both Kalamazoo and Ann Arbor, where the company operates major R&D centers. Pfizer employs about 5,200 people in Kalamazoo County, where it has operations in research, manufacturing and animal-health in Kalamazoo, Portage and Richland Township. Another 2,600
DETROIT - Early registration for the MichBio Expo 2005 opened Monday. The Expo is MichBio?s daylong event for professionals from across the life sciences spectrum and at every stage of business development, which will be held Sept. 29 at the Cobo Exhibition and Conference Center in downtown Detroit. The event features a life sciences conference
LANSING - As the embryonic stem cell research bills from Rep. Andy Meisner (D-Ferndale) prepare to wind through the Legislature, lawmakers in other states and Congress are also drafting laws of their own that would fund the controversial medical practice that would be used to advance life sciences. Although the debate over embryonic stem cell
GRAND RAPIDS ? The Van Andel Tuesday unveiled plans for a $150 million expansion of its medical research and education complex in downtown Grand Rapids in the heart of the city?s health-care district. Ground will be broken next spring on the 280,000 square foot addition to the west side of the original 186,000 square foot
DETROIT ? It?s not often that a Michigan life sciences company gets mentioned as one of the best in the world. But such kudos increasingly are going to Asterand, a human tissue and blood bank for commercial and academic research. The company was co-founded five years ago by Randal Charlton, the current chairman of MichBio,
ANN ARBOR ? The impact of Pfizer Inc.?s $1.3 billion acquisition of Esperion Therapeutics continues to be felt in the Michigan life sciences industry a year after the deal closed. The incredibly lucrative Esperion exit was by far the biggest for any Michigan technology company this far, providing the state with a poster child to
ANN ARBOR - Aastrom Biosciences has expanded the U.S. Phase I/II clinical trial of its adult stem cell-based Tissue Repair Cells in the treatment of severe long bone non-union fractures to include the Department of Orthopedic Surgery at William Beaumont Hospital, the third U.S. site engaged in the trial. The Principal Investigator for Beaumont, Dr.
ANN ARBOR - Genetics Squared has appointed Dr. Peter Lenehan as chief medical officer and Dr. David Fry chief science officer, former targeted oncology drug development team members at Pfizer and Parke-Davis/Warner-Lambert. "Genetics Squared is very excited to add these two exceptional individuals to its management team," said president and CEO John Freshley. "They have
MIDLAND ? One of the state?s largest technology companies, Dow Corning Life Sciences, will meet with the leaders of the next generation of biotechnology in Michigan next month at a conference that takes a look at the current state of Life Sciences and beyond. The conference is co hosted by Michigan State University, Midland Tomorrow,